Market Introduction
Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. This helps in the previous detection of disease, less invasive diagnostics, allows faster drug development, and is expected to be the effective treatment.
Market Overview and Dynamics
The Asia Pacific neurological biomarker market is expected to reach US$ 2,620.63 million by 2027 from US$ 927.05 million in 2019; it is estimated to grow at a CAGR of 14.1% from 2020 to 2027. The growth of the market is attributed to key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with use of biomarkers such as the absence of pre-analytical tests are among the major factors hindering the market growth.
Key Market Segments
The Asia Pacific neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.
Based on application, the Asia Pacific neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 –2027.
The Asia Pacific neurological biomarker market, by end user, is segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.
Major Sources and Companies Listed
A Few of the primary and secondary sources associated with this report on the Asia Pacific neurological biomarker market are the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and Biomarkers Across Neurodegenerative Diseases (BAND).
Reasons to buy the report
ASIA PACIFIC NEUROLOGICAL BIOMARKER SEGMENTATION
By Product
By Application
By End User
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 927.05 Million |
| Market Size by 2027 | US$ 2,620.63 Million |
| CAGR (2020 - 2027) | 14.1% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Neurological Biomarker Market is valued at US$ 927.05 Million in 2019, it is projected to reach US$ 2,620.63 Million by 2027.
As per our report Asia Pacific Neurological Biomarker Market, the market size is valued at US$ 927.05 Million in 2019, projecting it to reach US$ 2,620.63 Million by 2027. This translates to a CAGR of approximately 14.1% during the forecast period.
The Asia Pacific Neurological Biomarker Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Neurological Biomarker Market report:
The Asia Pacific Neurological Biomarker Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Neurological Biomarker Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Neurological Biomarker Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)